ERS Genomics licenses CRISPR patents to Cambridge University spin-out

The company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, ERS Genomics, has signed a patent licensing deal with DefiniGEN, a spin-out from the University of Cambridge, UK.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

ERS Genomics signs CRISPR patent deal on industrial applications

16 October 2018 ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.

Americas

ERS extends CRISPR influence with two licensing deals

20 September 2018 ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.

More on this story

Biotechnology

ERS Genomics signs CRISPR patent deal on industrial applications

16 October 2018 ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.

Americas

ERS extends CRISPR influence with two licensing deals

More on this story

Biotechnology

ERS Genomics signs CRISPR patent deal on industrial applications

16 October 2018 ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.

Americas

ERS extends CRISPR influence with two licensing deals